Mercator Medical (FRA:MM2) 3-Year RORE % : 2.80% (As of Mar. 2026)


FRA:MM2 Mercator Medical SA FRA:MM2
60 GF Score
Price €11.20
GF Value €11.29
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Mercator Medical 3-Year RORE %?

Mercator Medical FRA:MM2 +1.27% 60 3-Year RORE % is 2.80 as of Mar. 2026. GuruFocus rates FRA:MM2 with a GF Score™ of 60/100 and a GF Value™ of €11.29 (Fairly Valued). The stock has 2 warning signs investors should review. Among 782 Medical Devices & Instruments companies, Mercator Medical ranks better than 56.91% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Mercator Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 was 2.80%.

The industry rank for Mercator Medical's 3-Year RORE % or its related term are showing as below:

FRA:MM2's 3-Year RORE % is ranked better than
56.91% of 782 companies
in the Medical Devices & Instruments industry
Industry Median: -4.23 vs FRA:MM2: 2.80

Mercator Medical  (FRA:MM2) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Mercator Medical 3-Year RORE % Related Terms


Mercator Medical 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Mercator Medical's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercator Medical 3-Year RORE % Chart

Mercator Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.60 -95.64 -205.22 -144.43 87.65

Mercator Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -200.57 -184.81 -214.94 87.65 2.80

FRA:MM2 vs ISRG, BDX, MDLN: 3-Year RORE % Comparison

For the Medical Instruments & Supplies subindustry, Mercator Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercator Medical 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mercator Medical's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Mercator Medical's 3-Year RORE % falls into.


FRA:MM2
60GF Score
Mercator Medical SA FRA:MM2
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercator Medical 3-Year RORE % Calculation

Mercator Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.285-0.226 )/( 2.074-0 )
=0.059/2.074
=2.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 2.80 mean?
Mercator Medical (FRA:MM2) has a 3-Year RORE % of 2.80 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mercator Medical and its competitors. According to the industry distribution chart, Mercator Medical ranks #337 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Mercator Medical's 3-Year RORE % too high?
Mercator Medical's current 3-Year RORE % is 2.80. Based on the distribution chart, Mercator Medical ranks #337 out of 782 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mercator Medical has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mercator Medical's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Mercator Medical ranks #337 out of 782 companies for 3-Year RORE %. This puts Mercator Medical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mercator Medical and its competitors. Mercator Medical's current 3-Year RORE % is 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercator Medical stock overvalued right now?
Based on GuruFocus' analysis, Mercator Medical (FRA:MM2) is currently considered Fairly Valued. The stock's GF Value™ is €11.29, compared to a current price of €11.20 — trading 0.8% below its estimated fair value. The current 3-Year RORE % is 2.80. Mercator Medical's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Mercator Medical (FRA:MM2), the current 3-Year RORE % is 2.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercator Medical (FRA:MM2) Overvalued in 2026?

Based on GuruFocus' analysis, Mercator Medical stock appears to be undervalued. The current stock price of €11.20 is trading 0.8% below its estimated GF Value™ of €11.29. GuruFocus considers Mercator Medical to be Fairly Valued.

Key valuation signals for FRA:MM2:

  • 3-Year RORE %: 2.80
  • GF Value™: €11.29 vs. price of €11.20 (0.8% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the FRA:MM2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mercator Medical Business Description

Other Exchanges MRC:Poland
Address Ulica H. Modrzejewska 30, Krakow, POL, 31-327
Mercator Medical SA produces and sells medical gloves and distributor of medical disposables. The company's products - mainly gloves, dressings, disposable clothing and surgical drapes. It operates in Europe and Russia.
60GF Score

Get the complete analysis for FRA:MM2

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.20
Price
€11.29
GF Value